Tumor Biology

, Volume 37, Issue 1, pp 1229–1236 | Cite as

A new application of plant virus nanoparticles as drug delivery in breast cancer

  • Neda Esfandiari
  • Mohsen Karimi Arzanani
  • Masoud Soleimani
  • Mina Kohi-Habibi
  • Winnie E. Svendsen
Original Article

Abstract

Nanoparticles based on non-pathogenic viruses have opened up a novel sector in nanotechnology. Viral nanoparticles based on plant viruses have clear advantages over any synthetic nanoparticles as they are biocompatible and biodegradable self-assembled and can be produced inexpensively on a large scale. From several such under-development platforms, only a few have been characterized in the target-specific drugs into the cells. Potato virus X is presented as a carrier of the chemotherapeutic drug Herceptin that is currently used as a targeted therapy in (HER2+) breast cancer patients. Here, we used nanoparticles formed from the potato virus X to conjugate the Herceptin (Trastuzumab) monoclonal antibody as a new option in specific targeting of breast cancer. Bioconjugation was performed by EDC/sulfo-n-hydroxysuccinimide (sulfo-NHS) in a two-step protocol. Then, the efficiency of conjugation was investigated by different methods, including sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Western blot, ELISA, Zetasizer, and transmission electron microscopy. SDS-PAGE and Western blot analysis confirmed an 82-kDa protein band that resulted from conjugation of potato virus X (PVX) coat protein (27 kDa) to heavy chain of Herceptin (55 kDa). Zeta potential values for conjugated particles, PVX, and HER were −7.05, −21.4, and −1.48, respectively. We investigated the efficiency of PVX-Herceptin to induce SK-OV-3 and SK-BR-3 cells (HER2 positive cell lines) apoptosis. We therefore counted cells and measured apoptosis by flow cytometry assay, then compared with Herceptin alone. Based on our data, we confirmed the conjugation of PVX and Herceptin. This study suggests that the PVX-Herceptin conjugates enable Herceptin to become more potential therapeutic tools.

Keywords

Plant viral nanoparticles Cancer Immunological test HER2+ cell lines 

Notes

Acknowledgement

We would like to express our appreciation for the cooperation we received from Stem Cell Technology Research Center and INSF throughout the project. The authors are grateful to DSMZ in Germany for TEM.

Conflict of interest

None.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Kukowska-Latallo J, Candido K, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65:5317–24.Google Scholar
  2. 2.
    Aliosmanoglu A, Basaran I. Nanotechnology in cancer treatment. J Nanomed Biotherapeutic Discov. 2012;2:107.CrossRefGoogle Scholar
  3. 3.
    Wen AM, Shukla S, Saxena P, Aljabali AA, Yildiz I, Dey S, et al. Interior engineering of a viral nanoparticle and its tumor homing properties. Biomacromolecules. 2012;13(12):3990–4001.Google Scholar
  4. 4.
    Klem MT, Willits D, Young M, Douglas T. 2-D array formation of genetically engineered viral cages on au surfaces and imaging by atomics force microscopy. J Am Chem Soc. 2003;125(36):10806–7.Google Scholar
  5. 5.
    Grasso S, Santi L. Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches. Int J Physiol Pathophysiol Pharmacol. 2010;2(2):161–178.Google Scholar
  6. 6.
    Steinmetz NF. Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine. 2010;6(5):634–41.Google Scholar
  7. 7.
    Lico C, Chen Q, Santi L. Viral vectors for production of recombinant proteins in plants. J Cell Physiol. 2008;216(2):366–77.CrossRefPubMedGoogle Scholar
  8. 8.
    Lewis JD, Destito G, Zijlstra A, Gonzalez MJ, Quigley JP, Manchester M, et al. Viral nanoparticles as tools for intravital vascular imaging. Nat Med. 2006;12(3):354–60.Google Scholar
  9. 9.
    Douglas T, Young M. Viruses: making friends with old foes. Science. 2006;312(5775):873–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Steinmetz NF, Mertens ME, Taurog RE, Johnson JE, Commandeur U, Fischer R, et al. Potato virus X as a novel platform for biomedical applications. Nano Lett. 2010;10(1):305–12.Google Scholar
  11. 11.
    Tran T, Engfeldt T, Orlova A, Sandström M, Feldwisch J, Abrahmsén L, et al. Tc-maEEE-Z (HER2:342), an affibody molecule-based tracer for the detection of HER2 exoression in malignant tumors. Bioconjug Chem. 2007;18:1956–64.Google Scholar
  12. 12.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.Google Scholar
  13. 13.
    Armuss A. Update breast cancer. Versicherungsmedizin. 2014;66(2):68–71.PubMedGoogle Scholar
  14. 14.
    Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.Google Scholar
  15. 15.
    Chen TJ, Cheng TH, Chen CY, Hsu SC, Cheng TL, Liu GC, et al. Targeted Herceptin–dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. JBIC, J Biol Inorg Chem. 2009;14(2):253–60.Google Scholar
  16. 16.
    Jayasinghe U, Salazar LF. Basic techniques in plant virology, fascicles CIP pathology. Lima, Peru: Dept. Technical Training Unit No.1; 1993.Google Scholar
  17. 17.
    Jung Y, Park HJ, Kim PH, Lee J, Hyung W, Yang J, et al. Retargeting of adenoviral gene delivery via Herceptin – PEG-adenovirus conjugates to breast cancer cells. J Control Release. 2007;123(2):164–71.Google Scholar
  18. 18.
    Hermanson G. Bioconjugate techniques. San Diego, New York, Boston: Academic; 1996.Google Scholar
  19. 19.
    Esfandiari N, Kohi-Habibi M, Hohn T, Pooggin MM. Complete genome sequence of an iranian isolate of potato virus x from the legume plant pisum sativum. Virus Genes. 2009;39(1):141–5.Google Scholar
  20. 20.
    Singh P, Prasuhn D, Yeh RM, Destito G, Rae CS, Osborn K, et al. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release. 2007;120(1):41–50.Google Scholar
  21. 21.
    Koudelka KJ, Destito G, Plummer EM, Trauger SA, Siuzdak G, Manchester M. et al. Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. PLoS Pathog. 2009;5(5):e1000417.Google Scholar
  22. 22.
    Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9(5):1909–15.Google Scholar
  23. 23.
    Aljabali AA, Shukla S, Lomonossoff GP, Steinmetz NF, Evans DJ. CPMV-DOX delivers. Mol Pharm. 20122013;10(1):3–10.Google Scholar
  24. 24.
    Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem. 2006;17:1109–15.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Neda Esfandiari
    • 1
    • 4
  • Mohsen Karimi Arzanani
    • 2
  • Masoud Soleimani
    • 3
  • Mina Kohi-Habibi
    • 4
  • Winnie E. Svendsen
    • 1
  1. 1.Department of Micro and NanotechnologyTechnical University of DenmarkLyngbyDenmark
  2. 2.Division of Hematology, Department of MedicineKarolinska Institute, Karolinska University HospitalStockholmSweden
  3. 3.Department of Hematology, Faculty of Medical ScienceTarbiat Modares UniversityTehranIran
  4. 4.Department of Plant Protection, Faculty of Sciences and Plant ProtectionTehran UniversityTehranIran

Personalised recommendations